Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019
15 Maio 2019 - 9:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell
therapies for the sports medicine and severe burn care markets,
today announced that Nick Colangelo, president and CEO, will
present the latest company overview at the 2019 UBS Global
Healthcare Conference in New York City on Wednesday, May 22, 2019
at 10:30am Eastern Time.
A live webcast of the presentation will be available on the
Investor Relations section of the Vericel Corporation website at:
http://investors.vcel.com
About Vericel CorporationVericel is a leader in
advanced cell therapies for the sports medicine and severe burn
care markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American commercial rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. © 2019 Vericel Corporation. NexoBrid® is a registered
trademark of MediWound Ltd. and is used under license to Vericel
Corporation. All rights reserved.
Global Media Contacts:David SchullRusso
Partners LLCDavid.schull@russopartnersllc.com+1 212-845-4271
(office)+1 858-717-2310 (mobile)
Karen ChaseRusso Partners LLCKaren.chase@russopartnersllc.com+1
646-942-5627 (office)+1 917-547-0434 (mobile)
Investor Contacts:Chad RubinSolebury
Troutcrubin@troutgroup.com+1 646-378-2947
Lee SternSolebury Troutlstern@troutgroup.com+1 646-378-2922
Vericel (NASDAQ:VCEL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Vericel (NASDAQ:VCEL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024